Skip to content

#自身免疫

Today 0 items
Oct 7Wed
  1. nature.com40

    Next-generation immune cell engagers for B cell depletion in autoimmune diseases

    Nature Reviews Drug Discovery has published a review of immune cell engagers as a strategy for deep B cell depletion in autoimmune diseases. It covers their mechanisms, clinical development and next-generation designs, including T cell, natural killer cell and gamma-delta T cell-engaging formats. It also draws lessons from haematological malignancies to improve the efficacy, safety and durability of immune modulation.

  2. medicalxpress.com55

    International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases

    A group of 31 international experts has published updated consensus recommendations in The Lancet Rheumatology on using CAR T-cell therapy for severe, treatment-refractory autoimmune diseases. The 2026 recommendations, developed by EBMT, ISCT and JACIE with input from EULAR and ECTRIMS, update the first best-practice guidance from 2024 and cover patient selection, treatment in experienced FACT/JACIE-accredited centers, and reporting of patient data to the EBMT Registry. The panel calls for treatment within clinical trials where possible and lists larger controlled trials, biomarkers and novel CAR targets as research priorities.

    Why it matters: New international guidance shapes how clinicians select and manage CAR T-cell patients in autoimmune disease, a fast-growing off-cancer use.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org